Page last checked 2026-09-07

Research compound · not FDA-approved

Pinealon

Pinealon is a peptide three amino acids long, from the St Petersburg institute that also produced Epitalon. Papers abbreviate it EDR.

What matters first

Why people look it up: It is sold for memory, focus and mental sharpness in later life, as capsules or as powder for injection.
What the evidence shows: The memory claim rests on one sentence in one review. Following its three references leads to another review, a study in old rats, and a patent. People have taken it and the results were published, almost all in Russian. Two of those studies gave it alongside a second peptide, so neither separates the two. The one study that measured chemistry found two effects pointing the wrong way.
Dose status: Pinealon is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about Pinealon

Pinealon is three amino acids in a row: glutamic acid, aspartic acid, arginine, which the papers shorten to EDR. It was made at the St Petersburg institute that produced Epitalon, and it is sold for memory. People have taken it, and one paper says how much: railway crews swallowed 100 microgram capsules twice a day for two weeks. The memory claim it is known for is a different matter. Follow its references and they end at a review, a rat study and a patent.

Pinealon research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
Topic	Value
Strongest source	limited human data
FDA approval	Not FDA-approved
Studied dosing	100 mcg twice a day for two weeks (railway locomotive crews; the endpoints were biological-age indicators and measures of adaptive capacity, and the abstract describes no control group) — from clinical trials
Typical vials	10 mg

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

What the evidence for Pinealon is

People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.

limited human data

What it establishes: It shows that people have received it and that some human information exists.
What it does not establish: It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.

Evidence snapshot and shareable image

Evidence snapshot

Foreign approval or limited human data

The fastest way to see what kind of evidence this page is built on.

Regulation: Not FDA-approvedNo US prescribing label
Dose source: Human study1 reported dose row
Safety evidence: 2 listed safety findingsCommon and serious effects shown apart
Sources: 2 cited sourcesMedical review complete · 2026-09-07

Open the shareable evidence image

Pinealon at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Where Pinealon is in clinical trials

No trial of this compound is registered on ClinicalTrials.gov.

That is worth sitting with. Nobody has registered a study to find out whether Pinealon works in people, so no result is coming and no date is worth waiting for. Sellers are not waiting for that work either.

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-27

Every compound we track, and what stage each one has reached →

Regulatory status

FDA has approved nothing under this name, and no Pinealon study appears on any trial registry anywhere.

Nearly the whole literature comes from one institute in St Petersburg and the journals around it. The same senior author runs through it, and the patents are in the same hands. That is not a language problem.

A finding nobody independent has repeated carries the weight of one lab’s claim. The one published human quantity was a capsule people swallowed, twice a day, so nothing stands behind putting this in a syringe.

Full regulatory tracker →

Where to go next on Pinealon

The related pages keep each topic with its evidence.

Why pinealon carries no boxed warning

10 standing caveats on the pinealon page, written out rather than implied.

Pinealon vial and water in the pinealon dosage calculator

Water volumes of 2 mL and 3 mL are preset from the pinealon page.

Reconstituting pinealon at 10 mg, step by step

The 10 mg pinealon table itself, not a general rule applied to an unrelated vial size.

Take the pinealon arithmetic to any other vial

Concentration, units per draw and draws per vial, including Pinealon

Where pinealon sits among the dose schedules

2 of 42 pages carry a labeled schedule and 33 carry none, with pinealon as one example

Which compounds are still in trials besides pinealon

Compounds with no registered trial are counted as exactly that, including pinealon

The dated regulatory page for pinealon and the rest

Every entry cites its source. It comes from the Federal Register or fda.gov, with pinealon as context

Uses and approval status for pinealon and other compounds

Browse the wider compound library for background on pinealon.

How each pinealon claim is checked

Source definitions and the checks that enforce them, including the source for pinealon.

Safety notes

The memory claim this peptide is known for does not survive its own references. The review stating it cites three sources. They are another review, a study in old rats, and an Israeli patent held by that review’s own senior author. No primary report of the 72 patients it describes was reachable
The one published quantity given to people was 100 micrograms in a capsule, swallowed, twice a day for two weeks. It was not injected. Nothing published supports moving it into a syringe
That study describes no control group, was not registered on any trial registry, and is in Russian
The one human study that measured chemistry found two things against the compound. One was prooxidant activity, the opposite of what it is sold for. The other was a fall in CD34+ stem-cell markers, which the authors read as blood-cell production being held back
In that study the comparison peptide, Vesugen, outperformed Pinealon — a result from the same group that developed both
Two of the four human studies gave Pinealon combined with Vesugen rather than on its own, so nothing in them separates the two
Almost the whole literature comes from one institute in St Petersburg. The same senior author runs through it and the patents are in the same hands. No independent group has reproduced any of it
A ClinicalTrials.gov search on 13 August 2026 found no registered study of this peptide. A search on the sequence Glu-Asp-Arg returns 26 studies and none of them is of it. They match on three free amino acids in nutrition protocols
Most of what has been measured is not an outcome in a person. It is spines on mouse neurons in culture, caspase-3 in rat brain, antioxidant enzymes in rat cells, serotonin in cortical cells
One hundred micrograms is a hundredth of a 10 milligram vial. Drawn from that vial it is three units on a U-100 barrel at best. That is the edge of what a person can measure by eye

Questions about Pinealon

Is Pinealon FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is Pinealon taken?

By mouth, as something swallowed, twice a day.

How does Pinealon differ from the other compounds in this class?

Pinealon has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.

What is not known about Pinealon?

It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.

2primary sources, each with the day we read it — open the documents used on this page